<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03438266</url>
  </required_header>
  <id_info>
    <org_study_id>1650-801-008</org_study_id>
    <nct_id>NCT03438266</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula</brief_title>
  <official_title>A Multicenter, Single-blind, Randomized, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM VOLUMA XC
      (hereafter VOLUMA XC) injectable gel using cannula in subjects seeking correction of
      age-related volume deficit in the mid-face.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Anticipated">September 12, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mid-Face Volume Deficit Scale</measure>
    <time_frame>Month 1</time_frame>
    <description>The EI will assess the participants overall improvement from baseline using Mid-Face Volume Deficit Scale (MFVDS) where 0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = significant, 5 = severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction change from baseline with Cheeks module of the FACE-Q</measure>
    <time_frame>Month 1</time_frame>
    <description>The subjects will complete the Satisfaction with Cheeks module of the FACE-Q questionnaire. Visit will be summarized with descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Month 3</time_frame>
    <description>Subject's reported and investigator's assessed adverse events will be collected and monitored as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Age-related Volume Deficit in the Mid-face</condition>
  <arm_group>
    <arm_group_label>JUVÉDERM VOLUMA® XC injectable gel with cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have 1 cheek injected with JUVÉDERM VOLUMA® XC injectable gel with a cannula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JUVÉDERM VOLUMA® XC injectable gel with needle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will have 1 cheek injected with JUVÉDERM VOLUMA®XC injectable gel with a needle</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVÉDERM VOLUMA® XC injectable gel cannula side</intervention_name>
    <description>Subjects will have 1 cheek treated with JUVÉDERM VOLUMA XC injectable gel with a cannula</description>
    <arm_group_label>JUVÉDERM VOLUMA® XC injectable gel with cannula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVÉDERM VOLUMA® XC injectable gel needle side</intervention_name>
    <description>Subjects will have 1 cheek treated with JUVÉDERM VOLUMA XC injectable gel with a needle</description>
    <arm_group_label>JUVÉDERM VOLUMA® XC injectable gel with needle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female aged 35 to 65 (inclusive) years of age with overall mid-face severity of
        Moderate, Significant, or Severe for both cheeks on the MFVDS

        Exclusion criteria:

          -  Has any facial procedures or trauma that may interfere with the study procedures and
             results

          -  Has a history of anaphylaxis or allergy to lidocaine (or any amide-based
             anaesthetics), HA products, or Streptococcal protein, or is planning to undergo
             allergen desensitization therapy during the term of the study

          -  Has active autoimmune disease

          -  Has current cutaneous or mucosal inflammatory or infectious processes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Abrams</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Care and Laser Physicians of Beverly HillsSkin Care and Laser Physicians of Beverly Hills</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Art of Skin MD</name>
      <address>
        <city>Solana Beach</city>
        <state>California</state>
        <zip>92075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baumann Cosmetic and Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Dermatology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Laser &amp; Surgery Specialists of NY/NJ</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhoda S. Narins, MD, PC</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aesthetic Solutions, PA</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com/</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR‐CTRegistration@Allergan.com for assistance.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

